Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

Health Canada has approved Puma Biotechnology Inc's (NASDAQ:PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Knight Therapeutics Inc (OTC:KHTRF) has the exclusive right to commercialize Nerlynx in Canada.
Nerlynx is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2, and HER4.
Price Action: PBYI shares are down 2.49% at $8.60 during the market session on the last check Tuesday.